Asset Details
Do you wish to reserve the book?
TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD
Do you wish to request the book?
TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD
2025
Overview
Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is an umbrella term used to describe a group of autoimmune conditions characterized by chronic, relapsing inflammation of the gastrointestinal tract. The tumour necrosis factor superfamily member 14 (TNFSF14), also known as LIGHT, is a pleiotropic cytokine with diverse roles in immune regulation. Here, we review the multifaceted involvement of LIGHT in intestinal inflammation, particularly its dual capacity to both promote immune activation and facilitate inflammation resolution in the context of IBD. We explore the molecular mechanisms of LIGHT signalling through its receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin-β Receptor (LTβR), and how these distinct interactions dictate its pro-inflammatory or regulatory functions. Finally, we review the therapeutic potential of targeting this pathway, highlighting the results of recent clinical trials and exploring future strategies aimed at restoring immune homeostasis in patients with IBD.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ BTLA (B and T lymphocyte attenuator)
/ Genes
/ Humans
/ inflammatory bowel disease (IBD)
/ Inflammatory Bowel Diseases - immunology
/ Inflammatory Bowel Diseases - metabolism
/ Intestinal Mucosa - immunology
/ Intestinal Mucosa - metabolism
/ Kinases
/ Ligands
/ Light
/ LTβR (Lymphotoxin-β receptor)
/ Lymphoma
/ Lymphotoxin beta Receptor - immunology
/ Lymphotoxin beta Receptor - metabolism
/ Proteins
/ Receptors, Tumor Necrosis Factor, Member 14 - immunology
/ Receptors, Tumor Necrosis Factor, Member 14 - metabolism
/ Tumor Necrosis Factor Ligand Superfamily Member 14 - immunology
/ Tumor Necrosis Factor Ligand Superfamily Member 14 - metabolism
